Healthcare Industry News: broad-spectrum antimicrobial
News Release - June 15, 2007
KCI Enters into Exclusive Worldwide License with NovaBay for NeutroPhase(TM) Wound Treatment Solution TechnologySAN ANTONIO--(HSMN NewsFeed)--Kinetic Concepts, Inc. (NYSE:KCI ), a global medical technology company with leadership positions in advanced wound care and therapeutic surfaces, today announced that it has entered into an exclusive worldwide license with NovaBay Pharmaceuticals, Inc. for its proprietary NeutroPhase topical solution technology in the field of wound healing. NeutroPhase is a stable, rapid-acting solution containing hypochlorous acid, which is known to kill a broad range of bacteria in seconds. KCI intends to develop and commercialize NeutroPhase for the cleansing of wounds, and for use in combination with KCI's proprietary V.A.C.® instillation therapies.
"We are pleased to acquire rights to the NeutroPhase technology, which further broadens KCI's product offerings in advanced wound care," said Catherine M. Burzik, President and Chief Executive Officer of KCI. "Our plans to commercialize NeutroPhase as both a disinfection agent, and in combination with V.A.C. Instill® Wound Therapy, will provide caregivers with new options for the treatment and active management of wound infections."
NeutroPhase is a stable, diluted solution of hypochlorous acid in saline with broad-spectrum antimicrobial properties, which was developed to emulate molecules naturally produced by the body when white blood cells defend against bacteria. The solution has been shown not to harm cells and is rapidly effective against common wound pathogens at concentrations 200 times lower than that toxic to human cells. The characteristics and mechanisms of action of NeutroPhase make it highly unlikely that resistant strains of bacteria could develop over time.
Kinetic Concepts, Inc. is a global medical technology company with leadership positions in advanced wound-care and therapeutic surfaces. We design, manufacture, market and service a wide range of proprietary products that can improve clinical outcomes and can help reduce the overall cost of patient care. Our advanced wound-care systems incorporate our proprietary V.A.C. Therapy technology, which has been demonstrated clinically to help promote wound healing through unique mechanisms of action and can help reduce the cost of treating patients with serious wounds. Our therapeutic surfaces, including specialty hospital beds, mattress replacement systems and overlays, are designed to address pulmonary complications associated with immobility, to prevent skin breakdown and assist caregivers in the safe and dignified handling of obese patients. We have an infrastructure designed to meet the specific needs of medical professionals and patients across all health care settings, including acute care hospitals, extended care organizations and patients' homes, both in the United States and abroad.
This press release contains forward-looking statements. These forward-looking statements are based on our current expectations and are subject to a number of risks and uncertainties. All information set forth in this release is as of its date, and we undertake no duty to update this information. More information about the company is described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, on file with the SEC and available at the SEC's website at www.sec.gov.
Source: Kinetic Concepts
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.